NCT00240500 - Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers | Biotech Hunter

Enrollment

109

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions

Hepatitis B

Interventions

BIOLOGICAL

Engerix™-B

In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.

Trial Locations (1)

10330

GSK Investigational Site, Bangkok